Adicet Bio, Inc. (ACET)

Market Cap	63.29M
Revenue (ttm)	n/a
Net Income (ttm)	-118.64M
Shares Out	83.25M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	257,122
Open	0.8020
Previous Close	0.8124
Day's Range	0.7583 - 0.8124
52-Week Range	0.4471 - 1.5700
Beta	1.61
Analysts	Buy
Price Target	5.33 (+601.13%)
Earnings Date	Nov 5, 2025

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodg...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1947
• Employees: 152
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET
• Website: https://www.adicetbio.com

Analyst Summary

According to 5 analysts, the average rating for ACET stock is "Buy." The 12-month stock price target is $5.33, which is an increase of 601.13% from the latest price.

Price Target

$5.33

(601.13% upside)

Analyst Consensus: Buy